Prof. Eliezer Flescher and his fellow researchers from The Sackler Faculty of Medicine in Tel Aviv have developed an anti cancer drug derived from the sweet smelling jasmine flower.

After a decade of research into the compound jasmonate extracted from the jasmine flower, Flescher and his research team are hopeful that an anti cancer drug based on jasmonate could be on the shelf in America within four years.

Initial human studies have proved successful with blood cancers and solid tumors responding to the jasmonate compound.

Results from preliminary research from Flescher and other research teams have shown methyl jasmonate to be a promising candidate for the treatment of prostate cancer, lung cancer, cervical cancer, breast cancer and leukemia.

Related Articles


Chinese Medicine May Reduce Chemotherapy Side Effects in Cancer Patients A centuries‑old traditional Chinese medicine may reduce the intestinal side effects of chemotherapy in cancer patients by stimulating gut cell division and reducing

Active Compounds in Green Tea Could Affect Prostate Cancer Progression According to results of a study, men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers

Hot Flashes Reduced With Acupuncture in Breast Cancer Patients According to a study, not only is acupuncture as effective as drug therapy at reducing hot flashes in breast cancer patients, it has the added benefit of potentially

How to Maximize the Cancer Fighting Power of Broccoli One of the American Cancer Society's key dietary recommendations to reduce the risk of cancer is to include cruciferous vegetables such as broccoli. Sulforaphane is

Incidence of Prostate Cancer and Consumption of Soybean The association between dietary factors and prostate cancer has been investigated and one explanation for the low incidence of prostate cancer in Asia could be high

References:
1. Flescher E. Tel Aviv University researchers are combating cancer with a jasmine-based drug. American Friends of Tel Aviv University.
2. Yeruva L, Pierre KJ, Carper SW, Elegbede JA, Toy BJ, Wang RC. Jasmonates induce apoptosis and cell cycle arrest in non-small cell lung cancer lines. Exp Lung Res. 2006 Nov-Dec;32(10):499-516. PMID: 17169856.
3. Flescher E. Jasmonates--a new family of anti-cancer agents. Anticancer Drugs. 2005 Oct;16(9):911-6. PMID: 16162967.
4. Ezekwudo DE, Wang RC, Elegbede JA. Methyl jasmonate induced apoptosis in human prostate carcinoma cells via 5-lipoxygenase dependent pathway. J Exp Ther Oncol. 2007;6(4):267-77. PMID: 18038760.
5. Yeruva L, Elegbede JA, Carper SW. Methyl jasmonate decreases membrane fluidity and induces apoptosis through tumor necrosis factor receptor 1 in breast cancer cells. Anticancer Drugs. 2008 Sep;19(8):766-76. PMID: 18690087.
6. Kniazhanski T, Jackman A, Heyfets A, Gonen P, Flescher E, Sherman L. Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells. Cancer Lett. 2008 Jul 1. PMID: 18599197.
7. Ishii Y, Kiyota H, Sakai S, Honma Y. Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. PMID: 15229618.
8. Photograph of jasminum polyanthum by KENPEI licensed under Creative Commons

Add comment

User Name (Required)

E-mail (Required - Never shown publicly)

Website (Optional)

Notify me of follow-up comments

If you cannot read the code click to refresh for a new code.

Add comment

Cancel